These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9064994)

  • 1. [CD95 (APO-1/Fas) and CD95-ligand (CD95L). Implications of these apoptosis mediating receptor/ligand systems in the pathogenesis of autoimmune diseases].
    Möller P; von Reyher U; Leithäuser F; Sträter J
    Verh Dtsch Ges Pathol; 1996; 80():12-20. PubMed ID: 9064994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular interactions in the lpr and gld models of systemic autoimmunity.
    Sobel ES
    Adv Dent Res; 1996 Apr; 10(1):76-80. PubMed ID: 8934931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice.
    Reap EA; Leslie D; Abrahams M; Eisenberg RA; Cohen PL
    J Immunol; 1995 Jan; 154(2):936-43. PubMed ID: 7529292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways.
    Mountz JD; Zhou T; Su X; Cheng J; Pierson M; Bluethmann H; Edwards CK
    Behring Inst Mitt; 1996 Oct; (97):200-19. PubMed ID: 8950477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
    Nagata S
    J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of murine hepatocyte death by membrane-bound CD95 (Fas/APO-1)-ligand: characterization of an in vitro system.
    Schlosser SF; Azzaroli F; Dao T; Hingorani R; Crispe IN; Boyer JL
    Hepatology; 2000 Oct; 32(4 Pt 1):779-85. PubMed ID: 11003622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand.
    Müller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH
    Eur J Immunol; 1995 Oct; 25(10):2996-9. PubMed ID: 7589104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS.
    Dhein J; Walczak H; Westendorp MO; Bäumler C; Stricker K; Frank R; Debatin KM; Krammer PH
    Behring Inst Mitt; 1995 Jun; (96):13-20. PubMed ID: 7575348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1).
    Zuliani C; Kleber S; Klussmann S; Wenger T; Kenzelmann M; Schreglmann N; Martinez A; del Rio JA; Soriano E; Vodrazka P; Kuner R; Groene HJ; Herr I; Krammer PH; Martin-Villalba A
    Cell Death Differ; 2006 Jan; 13(1):31-40. PubMed ID: 16003386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD95/CD95L interactions and their role in autoimmunity.
    Ricci-Vitiani L; Conticello C; Zeuner A; De Maria R
    Apoptosis; 2000 Nov; 5(5):419-24. PubMed ID: 11256883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
    Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
    J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia.
    Lamy T; Liu JH; Landowski TH; Dalton WS; Loughran TP
    Blood; 1998 Dec; 92(12):4771-7. PubMed ID: 9845544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of Fas and the costimulatory molecules B7-1 and B7-2 on peripheral lymphocytes in autoimmune B6/gld mice.
    Weintraub JP; Eisenberg RA; Cohen PL
    J Immunol; 1997 Oct; 159(8):4117-26. PubMed ID: 9379003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand.
    Zipp F; Martin R; Lichtenfels R; Roth W; Dichgans J; Krammer PH; Weller M
    J Immunol; 1997 Sep; 159(5):2108-15. PubMed ID: 9278296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Fas/FasL interactions in the regulation of B cell function.
    Jacobson BA; Rothstein TL; Marshak-Rothstein A
    Behring Inst Mitt; 1996 Oct; (97):185-99. PubMed ID: 8950476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
    Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
    Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for CD95 ligand in preventing graft rejection.
    Bellgrau D; Gold D; Selawry H; Moore J; Franzusoff A; Duke RC
    Nature; 1995 Oct; 377(6550):630-2. PubMed ID: 7566174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological and pathological consequences of mutations in both Fas and Fas ligand.
    Weintraub JP; Godfrey V; Wolthusen PA; Cheek RL; Eisenberg RA; Cohen PL
    Cell Immunol; 1998 May; 186(1):8-17. PubMed ID: 9637760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.